Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient
Objective: To report the case of a child diagnosed with polyarteritis nodosa (PAN) that was unresponsive to conventional treatment alone but improved with the addition of iloprost and bosentan to her drug regimen. Case Summary: A 3-year-old girl who had been diagnosed with PAN was referred to our ho...
Gespeichert in:
Veröffentlicht in: | The Annals of pharmacotherapy 2007-05, Vol.41 (5), p.885-890 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 890 |
---|---|
container_issue | 5 |
container_start_page | 885 |
container_title | The Annals of pharmacotherapy |
container_volume | 41 |
creator | Gonzalez-Fernandez, Maria Angeles Garcia-Consuegra, Julia |
description | Objective:
To report the case of a child diagnosed with polyarteritis nodosa (PAN) that was unresponsive to conventional treatment alone but improved with the addition of iloprost and bosentan to her drug regimen.
Case Summary:
A 3-year-old girl who had been diagnosed with PAN was referred to our hospital from another region. With conventional treatment of high doses of a corticosteroid and cyclophosphamide, her condition resolved. Six months later, our patient had a relapse that required hospital admission. In this second hospital stay, some cutaneous lesions evolved into digital necrosis. Off-label therapeutic alternatives, including a single dose (2 g/kg) of intravenous immunoglobulin (IVIG), intravenous iloprost 2 ng/kg/min over 6 h for 5 days and, approximately 4 wk later, oral bosentan 37.25 mg twice daily for 4 wk followed by 62.5 mg twice daily for 8 wk, were added to the conventional regimen to treat the serious cutaneous manifestations. Her fingers improved very slowly, and she was discharged on gradually tapered doses of oral corticosteroids, bosentan, and monthly pulsed injections of cyclophosphamide. The digital necrosis and other cutaneous lesions had resolved completely 6 months after the second discharge.
Discussion:
The dosages of IVIG and iloprost were based on those used for PAN, Raynaud's phenomenon, and digital necrosis in children. The use of bosentan for vasculitis had not been reported in children before the treatment of our patient, so its dosage was based on that used to produce vasodilation in children with pulmonary hypertension.
Conclusions:
Digital necrosis and cutaneous manifestations not resolved with conventional PAN treatment improved within 5 days with iloprost and 12 weeks with bosentan. |
doi_str_mv | 10.1345/aph.1H637 |
format | Article |
fullrecord | <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1345_aph_1H637</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1H637</sage_id><sourcerecordid>10.1345_aph.1H637</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-521b70046e36c0d91b1f600b9f1a3c01eae9e78bd659ef7169c716ff7e78f8db3</originalsourceid><addsrcrecordid>eNptkMtKAzEUhoMoVqsLX0CyUXAx9WQuycxSilqh2CJ1Hc7MJG3KdKYkqaVvb2oL3bg5Nz7-Ax8hdwwGLEmzZ1wvBmzEE3FGrliWxhGPBZyHGThEEOfQI9fOLQGgYHFxSXpMpJDlcXxFJtOu2aH1yhpvHP3s6s4h_VLOOI-tp76jw679Ua03XYsNnVmFfhVWalqKdKpqg96aik7Rm3C-IRcaG6duj71Pvt9eZ8NRNJ68fwxfxlGViNRHWcxKAZBylfAK6oKVTHOAstAMkwqYQlUokZc1zwqlBeNFFYrWIhx1XpdJnzwdcivbOWeVlmtrVmh3koHcS5FBivyTEtj7A7velCtVn8ijhQA8HAF0FTbaYlsZd-LyXPAi3gc9HjiHcyWX3cYGJe7fj8fAhZkvtsYq6VbYNOE_k9vtNmUyk3meJb9XC4Qa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient</title><source>MEDLINE</source><source>SAGE Journals</source><creator>Gonzalez-Fernandez, Maria Angeles ; Garcia-Consuegra, Julia</creator><creatorcontrib>Gonzalez-Fernandez, Maria Angeles ; Garcia-Consuegra, Julia</creatorcontrib><description>Objective:
To report the case of a child diagnosed with polyarteritis nodosa (PAN) that was unresponsive to conventional treatment alone but improved with the addition of iloprost and bosentan to her drug regimen.
Case Summary:
A 3-year-old girl who had been diagnosed with PAN was referred to our hospital from another region. With conventional treatment of high doses of a corticosteroid and cyclophosphamide, her condition resolved. Six months later, our patient had a relapse that required hospital admission. In this second hospital stay, some cutaneous lesions evolved into digital necrosis. Off-label therapeutic alternatives, including a single dose (2 g/kg) of intravenous immunoglobulin (IVIG), intravenous iloprost 2 ng/kg/min over 6 h for 5 days and, approximately 4 wk later, oral bosentan 37.25 mg twice daily for 4 wk followed by 62.5 mg twice daily for 8 wk, were added to the conventional regimen to treat the serious cutaneous manifestations. Her fingers improved very slowly, and she was discharged on gradually tapered doses of oral corticosteroids, bosentan, and monthly pulsed injections of cyclophosphamide. The digital necrosis and other cutaneous lesions had resolved completely 6 months after the second discharge.
Discussion:
The dosages of IVIG and iloprost were based on those used for PAN, Raynaud's phenomenon, and digital necrosis in children. The use of bosentan for vasculitis had not been reported in children before the treatment of our patient, so its dosage was based on that used to produce vasodilation in children with pulmonary hypertension.
Conclusions:
Digital necrosis and cutaneous manifestations not resolved with conventional PAN treatment improved within 5 days with iloprost and 12 weeks with bosentan.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1H637</identifier><identifier>PMID: 17405822</identifier><identifier>CODEN: APHRER</identifier><language>eng</language><publisher>Los Angeles, CA: Harvey Whitney Books</publisher><subject>Anti-Inflammatory Agents - therapeutic use ; Antihypertensive Agents - therapeutic use ; Arthralgia - etiology ; Azathioprine - therapeutic use ; Biological and medical sciences ; Child, Preschool ; Cyclophosphamide - therapeutic use ; Female ; Fever - etiology ; Humans ; Iloprost - therapeutic use ; Immunoglobulins, Intravenous - therapeutic use ; Immunosuppressive Agents - therapeutic use ; Medical sciences ; Methylprednisolone - therapeutic use ; Pharmacology. Drug treatments ; Polyarteritis Nodosa - drug therapy ; Polyarteritis Nodosa - pathology ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Sulfonamides - therapeutic use ; Vasodilator Agents - therapeutic use</subject><ispartof>The Annals of pharmacotherapy, 2007-05, Vol.41 (5), p.885-890</ispartof><rights>2007 Harvey Whitney Books Company</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-521b70046e36c0d91b1f600b9f1a3c01eae9e78bd659ef7169c716ff7e78f8db3</citedby><cites>FETCH-LOGICAL-c374t-521b70046e36c0d91b1f600b9f1a3c01eae9e78bd659ef7169c716ff7e78f8db3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1345/aph.1H637$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1345/aph.1H637$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18876927$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17405822$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gonzalez-Fernandez, Maria Angeles</creatorcontrib><creatorcontrib>Garcia-Consuegra, Julia</creatorcontrib><title>Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>Objective:
To report the case of a child diagnosed with polyarteritis nodosa (PAN) that was unresponsive to conventional treatment alone but improved with the addition of iloprost and bosentan to her drug regimen.
Case Summary:
A 3-year-old girl who had been diagnosed with PAN was referred to our hospital from another region. With conventional treatment of high doses of a corticosteroid and cyclophosphamide, her condition resolved. Six months later, our patient had a relapse that required hospital admission. In this second hospital stay, some cutaneous lesions evolved into digital necrosis. Off-label therapeutic alternatives, including a single dose (2 g/kg) of intravenous immunoglobulin (IVIG), intravenous iloprost 2 ng/kg/min over 6 h for 5 days and, approximately 4 wk later, oral bosentan 37.25 mg twice daily for 4 wk followed by 62.5 mg twice daily for 8 wk, were added to the conventional regimen to treat the serious cutaneous manifestations. Her fingers improved very slowly, and she was discharged on gradually tapered doses of oral corticosteroids, bosentan, and monthly pulsed injections of cyclophosphamide. The digital necrosis and other cutaneous lesions had resolved completely 6 months after the second discharge.
Discussion:
The dosages of IVIG and iloprost were based on those used for PAN, Raynaud's phenomenon, and digital necrosis in children. The use of bosentan for vasculitis had not been reported in children before the treatment of our patient, so its dosage was based on that used to produce vasodilation in children with pulmonary hypertension.
Conclusions:
Digital necrosis and cutaneous manifestations not resolved with conventional PAN treatment improved within 5 days with iloprost and 12 weeks with bosentan.</description><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Arthralgia - etiology</subject><subject>Azathioprine - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child, Preschool</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Female</subject><subject>Fever - etiology</subject><subject>Humans</subject><subject>Iloprost - therapeutic use</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Medical sciences</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Polyarteritis Nodosa - drug therapy</subject><subject>Polyarteritis Nodosa - pathology</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Sulfonamides - therapeutic use</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkMtKAzEUhoMoVqsLX0CyUXAx9WQuycxSilqh2CJ1Hc7MJG3KdKYkqaVvb2oL3bg5Nz7-Ax8hdwwGLEmzZ1wvBmzEE3FGrliWxhGPBZyHGThEEOfQI9fOLQGgYHFxSXpMpJDlcXxFJtOu2aH1yhpvHP3s6s4h_VLOOI-tp76jw679Ua03XYsNnVmFfhVWalqKdKpqg96aik7Rm3C-IRcaG6duj71Pvt9eZ8NRNJ68fwxfxlGViNRHWcxKAZBylfAK6oKVTHOAstAMkwqYQlUokZc1zwqlBeNFFYrWIhx1XpdJnzwdcivbOWeVlmtrVmh3koHcS5FBivyTEtj7A7velCtVn8ijhQA8HAF0FTbaYlsZd-LyXPAi3gc9HjiHcyWX3cYGJe7fj8fAhZkvtsYq6VbYNOE_k9vtNmUyk3meJb9XC4Qa</recordid><startdate>20070501</startdate><enddate>20070501</enddate><creator>Gonzalez-Fernandez, Maria Angeles</creator><creator>Garcia-Consuegra, Julia</creator><general>Harvey Whitney Books</general><general>SAGE Publications</general><general>Whitney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20070501</creationdate><title>Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient</title><author>Gonzalez-Fernandez, Maria Angeles ; Garcia-Consuegra, Julia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-521b70046e36c0d91b1f600b9f1a3c01eae9e78bd659ef7169c716ff7e78f8db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Arthralgia - etiology</topic><topic>Azathioprine - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child, Preschool</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Female</topic><topic>Fever - etiology</topic><topic>Humans</topic><topic>Iloprost - therapeutic use</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Medical sciences</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Polyarteritis Nodosa - drug therapy</topic><topic>Polyarteritis Nodosa - pathology</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Sulfonamides - therapeutic use</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonzalez-Fernandez, Maria Angeles</creatorcontrib><creatorcontrib>Garcia-Consuegra, Julia</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonzalez-Fernandez, Maria Angeles</au><au>Garcia-Consuegra, Julia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2007-05-01</date><risdate>2007</risdate><volume>41</volume><issue>5</issue><spage>885</spage><epage>890</epage><pages>885-890</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><coden>APHRER</coden><abstract>Objective:
To report the case of a child diagnosed with polyarteritis nodosa (PAN) that was unresponsive to conventional treatment alone but improved with the addition of iloprost and bosentan to her drug regimen.
Case Summary:
A 3-year-old girl who had been diagnosed with PAN was referred to our hospital from another region. With conventional treatment of high doses of a corticosteroid and cyclophosphamide, her condition resolved. Six months later, our patient had a relapse that required hospital admission. In this second hospital stay, some cutaneous lesions evolved into digital necrosis. Off-label therapeutic alternatives, including a single dose (2 g/kg) of intravenous immunoglobulin (IVIG), intravenous iloprost 2 ng/kg/min over 6 h for 5 days and, approximately 4 wk later, oral bosentan 37.25 mg twice daily for 4 wk followed by 62.5 mg twice daily for 8 wk, were added to the conventional regimen to treat the serious cutaneous manifestations. Her fingers improved very slowly, and she was discharged on gradually tapered doses of oral corticosteroids, bosentan, and monthly pulsed injections of cyclophosphamide. The digital necrosis and other cutaneous lesions had resolved completely 6 months after the second discharge.
Discussion:
The dosages of IVIG and iloprost were based on those used for PAN, Raynaud's phenomenon, and digital necrosis in children. The use of bosentan for vasculitis had not been reported in children before the treatment of our patient, so its dosage was based on that used to produce vasodilation in children with pulmonary hypertension.
Conclusions:
Digital necrosis and cutaneous manifestations not resolved with conventional PAN treatment improved within 5 days with iloprost and 12 weeks with bosentan.</abstract><cop>Los Angeles, CA</cop><pub>Harvey Whitney Books</pub><pmid>17405822</pmid><doi>10.1345/aph.1H637</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1060-0280 |
ispartof | The Annals of pharmacotherapy, 2007-05, Vol.41 (5), p.885-890 |
issn | 1060-0280 1542-6270 |
language | eng |
recordid | cdi_crossref_primary_10_1345_aph_1H637 |
source | MEDLINE; SAGE Journals |
subjects | Anti-Inflammatory Agents - therapeutic use Antihypertensive Agents - therapeutic use Arthralgia - etiology Azathioprine - therapeutic use Biological and medical sciences Child, Preschool Cyclophosphamide - therapeutic use Female Fever - etiology Humans Iloprost - therapeutic use Immunoglobulins, Intravenous - therapeutic use Immunosuppressive Agents - therapeutic use Medical sciences Methylprednisolone - therapeutic use Pharmacology. Drug treatments Polyarteritis Nodosa - drug therapy Polyarteritis Nodosa - pathology Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Sulfonamides - therapeutic use Vasodilator Agents - therapeutic use |
title | Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A46%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Polyarteritis%20Nodosa%20Resistant%20to%20Conventional%20Treatment%20in%20a%20Pediatric%20Patient&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Gonzalez-Fernandez,%20Maria%20Angeles&rft.date=2007-05-01&rft.volume=41&rft.issue=5&rft.spage=885&rft.epage=890&rft.pages=885-890&rft.issn=1060-0280&rft.eissn=1542-6270&rft.coden=APHRER&rft_id=info:doi/10.1345/aph.1H637&rft_dat=%3Csage_cross%3E10.1345_aph.1H637%3C/sage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17405822&rft_sage_id=10.1345_aph.1H637&rfr_iscdi=true |